Within two years of the last TP53-negative sample, the TP53 mutant subclone was fully dominant and accompanied by extensive structural rearrangements shortly before clinical AML diagnosis, consistent with rapid clonal expansion and genomic instability. This evidence concerns the gene TP53 and acute myeloid leukemia.